Abstract
Technological innovations have changed the landscape of diagnosis and treatment of limited-stage small cell lung cancer. Advances including positron emission tomography (PET) staging, magnetic resonance imaging (MRI) of the brain, intensity-modulated radiation therapy, and dose escalation using image guided radiation therapy have been introduced into practice without phase III evidence. To determine the impact of these technologies on outcomes for limited-stage small cell lung carcinoma (LS-SCLC) in the contemporary period, we retrospectively reviewed patients definitively treated for this disease during the last decade at our institution.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
